Churg-Strauss Syndrome: Singulair or Silicone (or both?)

Paula R. David¹,², Amir Dagan MD², Maartje Colaris MD⁴, Mintsje de Boer MD⁵, Jan W. Cohen Tervaert MD⁵ and Yehuda Shoenfeld MD FRCP MCR¹,³

¹Zabludowicz Center for Autoimmune Diseases and ²Department of Internal Medicine F, Sheba Medical Center, Tel Hashomer, Israel
³Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
⁴Faculdade de Ciências Médicas, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brasil
⁵Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands

KEY WORDS: autoimmune/inflammatory syndrome induced by adjuvants (ASIA), silicone, Churg-Strauss syndrome (CSS), montelukast, asthma

Leukotriene receptor antagonists have been used successfully for asthma treatment. These drugs could induce eosinophilic granulomatosis with polyangiitis (EGPA), previously known as Churg-Strauss syndrome (CSS), in patients who are prone to develop autoimmune diseases [1]. One of the most important adjuvants responsible for developing ASIA (autoimmune/inflammatory syndrome induced by adjuvants) is silicone. Patients with silicone-induced ASIA may develop CSS [2-4]. We present two asthmatic female patients diagnosed with CSS who had been exposed to both risk factors: montelukast and silicone. We discuss here how these risk factors could be associated with the development of CSS.

PATIENT DESCRIPTIONS

A 63 year old female patient presented with asthma exacerbation of 2 months duration, bilateral paresthesia in her hands, wrists and right thigh, and recurrent paranasal sinusitis. She had been diagnosed with asthma in 2005 when she was 53 years old, and since then had tried many different treatments. She had been taking systemic corticosteroids and montelukast for the last 3 years and her asthma was stable, until a few months before the current presentation when the exacerbation returned. She described a sensation of fullness in both nostrils and recurrent paranasal sinusitis. A head computed tomography (CT) confirmed pansinusitis. She also had nasal polyposis, for which she had undergone functional endoscopic sinus surgery (FESS) in 2008.

She was referred due to a painful paresthesia in her right hand that appeared a month before her presentation. It eventually subsided but reoccurred one week later, now in her left hand and right leg simultaneously. Electromyography confirmed the hypothesis of mononeuritis multiplex.

In 2007, she underwent a mammoplasty with silicone breast implants. Her last mammography, one year ago, demonstrated that the implant had ruptured and was leaking silicone. No other findings in her or her family’s medical history were relevant, other than her positive skin allergy tests to house mites and her mother’s polyarthritis.

Routine blood laboratory tests were all within the normal range, except for eosinophils which were increased (6300/µl), C-reactive protein (CRP) that was lightly elevated (19.5 mg/L), and high levels of immunoglobulin (Ig) E (545.7/UL). Her urine showed no abnormalities. Her induced sputum demonstrated 13% eosinophils. She was positive for anti-myeloperoxidase, despite being negative for c-ANCA and p-ANCA (cytoplasmic and perinuclear antineutrophil cytoplasmic antibodies, respectively). Rheumatoid factor (RF), antinuclear antibody (ANA), and proteinase 3 antibodies (anti-PR3) were all normal. There were no alterations in components of the complement system: C3 was 147 mg/dl and C4 was 28 mg/dl. There was no infiltration on chest X-ray, and a biopsy to seek extravascular eosinophil infiltration was not performed. She met four of the six American College of Rheumatology (ACR) criteria for CSS: asthma, history of allergies, extravascular eosinophilia, and paranasal sinus abnormalities, configuring a probable case of CSS, with positive anti-myeloperoxidase.

Our second patient was a 61 year old female who presented with dyspnea, hemoptysis, pulmonary infiltrates and arthralgia. Her IgE level was high (330 U/L) and her eosinophils were 2300/mm³. She had been diagnosed previously with CSS. We consider this a possible relapse of the disease and restarted steroid treatment.

Her history disclosed implantation of bilateral silicone prostheses in 1980 when she was 26 years old. In 2000 the implant ruptured and was replaced by a water-based prosthesis. In 2003 she underwent another mammoplasty with a new silicone implantation.

Shortly after her first implant, she developed asthma and an allergy test to house dust mites was positive. In 2005, after her second exposure to silicone, she experienced more extensive allergies, with skin tests positive to house dust mites, grasses, dogs and cats, and her asthma became unstable. She was put on montelukast therapy.
She suffered recurrent sinusitis due to extensive nasal polyps. In 1998 a polypectomy was performed. Despite the surgery, she continued to have recurrent sinusitis. In 2000 she underwent a conchotomy and in 2005 an ethmoidectomy.

In 2007, she was diagnosed with asthma, mononeuritis multiplex, arthralgia, hypereosinophilia (10,200/mm³) and IgE of 2900 U/L. A test for ANCA (anti-neutrophilic cytoplasmic antibodies) was negative; she was found to have autoimmune thyroiditis with positive anti-thyroid peroxidase (anti-TPO). A skin biopsy showed leukocytoclastic vasculitis with predominant eosinophils. She was diagnosed with CSS, meeting all six American College of Rheumatology (ACR) criteria for CSS. There was no cardiac involvement. The montelukast was discontinued and she started taking prednisolone/cyclophosphamide (which after 3 months was switched to azathioprine) and thyrax. Since then, she had a relapsing respiratory tract infection with bronchiectasis and persisting recurrent nasal polyposis, with FESS being performed three times.

**COMMENT**

Churg-Strauss syndrome is a primary small and medium vessel necrotizing vasculitis that was first described in 1951 by Jacob Churg and Lotte Strauss. It is a member of the group of ANCA-associated vasculitides (AAV), even though ANCA may not necessarily be positive. The etiopathogenesis of CSS is still not clear but is presumed to be induced by a combination of genetic and environmental triggers. During recent years, researchers have sought some triggering factors for CSS. Those most suspected include infections, vaccination, desensitization, drugs (macrolides, carbamazepine, quinine, corticosteroid-sparing agents for asthma, leukotriene modifiers) and adjuvants. We have described two CSS patients with a history of montelukast treatment and silicone breast implants.

Montelukast, or Singularair® (Merck, USA) is a leukotriene receptor antagonist (LTRA). This class of drug has been used for asthma since the mid-1990s. It alleviates asthma by inhibiting the bond between cysteinyl-leukotrienes and their receptors in the airway cells, which prevents its sequelae (airway edema, smooth muscle contraction and pro-inflammatory effects).

A significant number of cases of CSS following LTRA therapy have been reported [1], prompting several theories to explain this association. Some authors believe that LTRA is prescribed for asthmatic patients with the most severe symptoms, which may actually be a prodromal phase of CSS. Others presume that the use of montelukast permits tapering of corticosteroid doses, thereby unmasking a preexisting condition; and 8% had three ACR criteria for CSS when they started using LTRA and which could be compatible with a possible prodromal phase of CSS. However, in 64% of the patients the disease could not be attributed to these hypotheses, showing a potential causal association between LTRA therapy and CSS [1].

Silicones are a family of polymers consisting of an inorganic silicone-oxygen backbone with organic side groups attached to the silicone atoms. Polydimethylsiloxane is the silicone used in medication. Having long been considered an inert substance, for many years it was deployed in liquid, solid or particulate form. It has since been proven to be active in our immune system. The case of an implant leaking silicone is clear evidence that silicone is not an inert substance. Some of its low molecular weight compounds, by physical migration or engulfment and transportation in the macrophages, spread through the organism (“bleeding”), causing a histiocytic reaction in distant points of the implant. This generates granulomas, called silicomas. Moreover, specific anti-polymer IgG selectively binding to silicone particles has been found in some patients [5].

ASIA (autoimmune/inflammatory syndrome induced by adjuvants) can be triggered by any kind of silicone implant [4,6]. In the Maastricht cohort study, 34 of 100 patients were diagnosed with autoimmune diseases after silicone transplant or infusion, including 3 patients with vasculitis and one with CSS [4,6]. Also reported was the case of a CSS patient who developed the disease 8 months after having a silicone intravitreal infusion for retinal detachment treatment [3].

Our patients are compatible with the hypotheses that montelukast could lead to CSS and that silicone could be a trigger for CSS in patients prone to develop autoimmune diseases. More than that, we believe that they synergistically contributed to the onset of CSS in the cases presented here.

Goren et al. [2] described four population groups at risk of developing ASIA and recommended that they avoid exposing themselves to silicone particles and other adjuvants. These include patients with prior documented reaction to an adjuvant, patients with established autoimmune conditions, patients with a history of allergic conditions or atopic disorders, and individuals prone to develop autoimmunity (either a genetic predisposition and/or relevant environmental triggers).

We contend that asthmatic patients on montelukast should not be exposed to silicone, and vice versa. In other words, we should not prescribe LTRA to individuals with silicone implants since they are at a higher risk for developing CSS.

A systematic study in New Zealand reviewed 140 cases of CSS in patients on montelukast reported by the Food and Drug Administration (FDA) Adverse Event Reporting System (AERS). It concluded that 9% of the cases already had the disease before initiation of the drug; 19% had tapered the corticosteroid dose, possibly unmasking a suppressed preexisting condition; and 8% had three ACR criteria for CSS when they started using LTRA and which could be compatible with a possible prodromal phase of CSS. However, in 64% of the patients the disease could not be attributed to these hypotheses, showing a potential causal association between LTRA therapy and CSS [1].
Correspondence
Dr. J.W. Cohen Tervaert
Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands
email: jw.cohentervaert@maastrichtuniversity.nl

References

Zika virus spreads to new areas – the Americas, May 2015 to January 2016
It is already known that Zika virus is a mosquito-borne flavivirus transmitted primarily by *Aedes aegypti* mosquitoes. Most infections are asymptomatic, and symptomatic disease is generally mild. In May 2015, the first local transmission of Zika virus in the region of the Americas was reported in Brazil. Following the spread of Zika virus in Brazil, there has been a marked reported increase in the number of infants born with microcephaly; it is not known how many of these cases are associated with Zika virus infection. By mid-January 2016, local Zika virus transmission had been reported to the Pan American Health Organization from 20 countries or territories in the region of the Americas; spread to other countries in the region is likely. Although local transmission of Zika virus has not been documented in the continental United States, infections have been reported among travelers visiting or returning to the U.S., and these will likely increase. Imported cases might result in local transmission in limited areas of the continental USA. With regard to public health practice, the best way to prevent Zika virus infection is to avoid mosquito bites by avoiding exposure and eliminating mosquito breeding areas. Until more is known, pregnant women should consider postponing travel to any area with ongoing Zika virus transmission. Health care providers should contact their state or local health department about testing patients with symptoms of Zika virus infection and a compatible travel history. *MMWR* 2016; 65: 55

Zika virus infection in pregnant women in Rio de Janeiro
Zika virus (ZIKV) has been linked to neonatal microcephaly. To characterize the spectrum of ZIKV disease in pregnancy, Patricia Brasil et al. followed patients in Rio de Janeiro to describe clinical manifestations in mothers and repercussions of acute ZIKV infection in fetuses. Of 88 women enrolled from September 2015 through February 2016, 72 (82%) tested positive for ZIKV in blood, urine, or both. The timing of acute ZIKV infection ranged from 5 to 38 weeks of gestation. Predominant clinical features included pruritic descending macular or maculopapular rash, arthralgias, conjunctival injection, and headache; 28% had fever (short-termed low-grade). Women who were positive for ZIKV were more likely than those who were ZIKV-negative to have maculopapular rash (44% vs. 12%, P = 0.02), conjunctival involvement (58% vs. 13%, P = 0.002), and lymphadenopathy (40% vs. 7%, P = 0.02). Fetal ultrasonography was performed in 42 ZIKV-positive women (58%) and in all ZIKV-negative women. Fetal abnormalities were detected by Doppler ultrasonography in 12 of the 42 ZIKV-positive women (29%) and in none of the 16 ZIKV-negative women. Adverse findings included fetal deaths at 36 and 38 weeks of gestation (2 fetuses), in utero growth restriction with or without microcephaly (5 fetuses), ventricular calcifications or other central nervous system (CNS) lesions (7 fetuses), and abnormal amniotic fluid volume or cerebral or umbilical artery flow (7 fetuses). To date, 8 of the 42 women in whom fetal ultrasonography was performed have delivered their babies, and the ultrasonographic findings have been confirmed. The authors conclude that despite mild clinical symptoms, ZIKV infection during pregnancy appears to be associated with grave outcomes, including fetal death, placental insufficiency, fetal growth restriction, and central nervous system injury. *N Engl J Med* 2016 doi: http://dx.doi.org/10.1056/NEJMoA1602412